
    
      This study will evaluate the safety and tolerability of IFN-g 1b in patients with advanced
      liver fibrosis and cirrhosis due to hepatitis C. This study will also evaluate whether IFN-g
      1b is effective in reducing the amount of fibrosis in the liver.
    
  